Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) and Synlogic (NASDAQ:SYBX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.
Profitability
This table compares Allarity Therapeutics and Synlogic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allarity Therapeutics | N/A | -152.77% | -46.50% |
| Synlogic | N/A | -26.47% | -18.00% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Allarity Therapeutics and Synlogic, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Synlogic | 0 | 0 | 0 | 0 | 0.00 |
Insider and Institutional Ownership
11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Allarity Therapeutics and Synlogic”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allarity Therapeutics | $320,000.00 | 43.25 | -$11.23 million | ($0.78) | -1.12 |
| Synlogic | $8,000.00 | 1,622.99 | -$23.36 million | ($0.06) | -17.67 |
Allarity Therapeutics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Allarity Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Summary
Synlogic beats Allarity Therapeutics on 7 of the 12 factors compared between the two stocks.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
About Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
